One of the biggest patient safety risks facing hospitals today is respiratory depression.
This is especially true for patients receiving opioids to help with pain management. In healthcare settings, more than half of medication-related deaths link to opioid usage. While bedside patient monitoring, pulse oximetry, and capnography help detect patient changes, these stand-alone devices are prone to undue nuisance alarms. This can cause alarm fatigue and missed alarms. Bernoulli helps to alleviate these challenges through connectivity of all devices and clinical surveillance. Further, real-time data paired with analytics help to identify early warning signs. Paired with centralized monitoring and alarm messages, the Bernoulli system is the best tool for early detection of respiratory depression.
Alarming Facts: The Risks of Respiratory Depression
- Patients receiving opioids are at risk for drug-induced respiratory depression. If not detected, this condition can quickly lead to anoxic brain injury or death.
- According to the Association for the Advancement of Medical Instrumentation (AAMI) Foundation, 50% of medication deaths are attributable to opioids, and each year more than 20,000 patients administered opioids experience respiratory depression arrests – costing the U.S. healthcare system $2 billion each year.
- One of the most common monitoring methods – periodic physical spot checks by direct-care clinical staff – can leave patients unmonitored up to 96% of the time.
- According to The Joint Commission’s Sentinel Event database, 29% of adverse events are related to improper patient monitoring.
With all these facts, it’s no surprise that “undetected opioid-induced respiratory depression” (OIRD) ranks as the 4th greatest technology threat for 2017 by ECRI Institute.